Key statistics
On Friday, Addex Therapeutics Ltd (ADXN:NAQ) closed at 7.90, 21.35% above the 52 week low of 6.51 set on Apr 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 7.99 |
|---|---|
| High | 7.99 |
| Low | 7.62 |
| Bid | 3.08 |
| Offer | 12.00 |
| Previous close | 7.70 |
| Average volume | 3.25k |
|---|---|
| Shares outstanding | 1.82m |
| Free float | 1.61m |
| P/E (TTM) | -- |
| Market cap | 14.18m USD |
| EPS (TTM) | -8.72 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 17:55 GMT.
More ▼
Announcements
- Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
- Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
- Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
- Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
- Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025
- Addex Increases Issued Share Capital to Create Treasury Shares
- Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
- Addex Appoints Bank of New York Mellon as Depositary Bank
- Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
More ▼
